XBRUHYL
Market cap154mUSD
Dec 20, Last price
5.30EUR
1D
-4.33%
1Q
-7.67%
IPO
-49.72%
Name
Hyloris Pharmaceuticals SA
Chart & Performance
P/E
—
P/S
71.11
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
3.52%
Rev. gr., 5y
87.11%
Revenues
2m
-29.28%
Net income
-15m
L+42.80%
CFO
-13m
L-2.63%
Profile
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 2,087 -29.28% | 2,951 -4.68% | 3,096 1,669.14% | |||||
Cost of revenue | 20,060 | 13,762 | 8,063 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (17,973) | (10,811) | (4,967) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 4 | 297 | ||||||
Tax Rate | ||||||||
NOPAT | (17,973) | (10,815) | (5,264) | |||||
Net income | (15,380) 42.80% | (10,770) -6.99% | (11,579) 62.03% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 17,169 | |||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 241 | 138 | 11,880 | |||||
Long-term debt | 3,261 | 1,632 | 583 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 343 | 300 | 1,000 | |||||
Net debt | (31,705) | (46,635) | (42,081) | |||||
| Cash flow | ||||||||
Cash from operating activities | (12,808) | (13,154) | (11,250) | |||||
CAPEX | (298) | (739) | (1,061) | |||||
Cash from investing activities | 9,889 | (1,239) | (3,075) | |||||
Cash from financing activities | (131) | 7,838 | (62) | |||||
FCF | (17,825) | (12,500) | (5,174) | |||||
| Balance | ||||||||
Cash | 30,406 | 43,926 | 50,540 | |||||
Long term investments | 4,801 | 4,479 | 4,004 | |||||
Excess cash | 35,103 | 48,257 | 54,389 | |||||
Stockholders' equity | (82,444) | (64,106) | (54,676) | |||||
Invested Capital | 123,607 | 120,336 | 114,673 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 28,000 | 27,199 | 25,833 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (17,625) | (10,615) | (4,830) | |||||
EV/EBITDA | ||||||||
Interest | 100 | 219 | 556 | |||||
Interest/NOPBT | ||||||||